Investment, Funding & Disinvestments

This new facility marks Lilly’s fourth major U.S. manufacturing project in recent years and adds to its broader domestic expansion strategy.

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

The new facility promises to revolutionize medical care for residents of Pleebo City and the surrounding communities, who have long endured the burden of traveling significant distances to access surgical services.

The strategic focus will center on three key areas: enhancing the product portfolio, accelerating digital transformation and e-commerce capabilities, and driving expansion into regional markets across the Middle East and Africa.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

The conference attracted regulators, manufacturers, healthcare providers, and industry stakeholders who gathered to examine priorities shaping modern healthcare delivery.

The hospital’s infrastructure includes approximately 240 patient rooms, 48 intensive care beds, seven operating theatres, and two catheterisation laboratories, enabling staff to deliver care across more than 40 specialized medical disciplines.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.